MEDIOLA: A phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours – new ovarian cancer cohorts

Authors :: M.J.A. de Jonge
M. Ferguson
Yvette Drew
Young-Ae Park
Ricardo H. Alvarez
P. Herbolsheimer
Anita Wolfer
C. Gresty
Helen K. Angell
Susan M. Domchek
Sook-Hee Hong
Bella Kaufman
M. E. Gore
Richard T. Penson
K. Meyer
Jennifer Brown
M. Lanasa
Source :: Annals of Oncology. 29:viii147
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Full Text Access

Tools